Neuland Labs Inaugurates New Manufacturing Facility Constructed for its Collaboration with Mitsubishi Healthcare Unit API Corporation

Neuland Laboratories Ltd, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, has opened a new manufacturing facility constructed as part of its collaboration with Tokyo-based API Corporation (APIC), a healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs, along with fine chemicals and reagents. The new facility, which is located in a Neuland complex in Pashamylaram, Hyderabad, is the first manufacturing facility that APIC has established outside of Japan. 

Pursuant to an agreement entered into in March 2013, Neuland constructed and will operate these manufacturing facilities dedicated to providing APIC with capacity for meeting the needs of its customers for pharmaceutical APIs and intermediates. 

Kiyoshi Kondo, President and CEO of APIC, stated: “We welcome the inauguration of our dedicated Neuland manufacturing facility, a world-class operation that has come online just a year after our collaboration agreement was signed. This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland, a company with a long history of outstanding quality and regulatory excellence.” 

“We are pleased to inaugurate these new state-of-the-art manufacturing facilities developed as part of our collaboration with APIC,” said Dr D.R. Rao, Chairman and Managing Director of Neuland Labs Ltd. “This arrangement allows APIC to expand their business in Japan in a timely and cost-effective way, while also helping to raise Neuland’s profile as a quality supplier of APIs and intermediates to the Japanese market.”